Gyre Therapeutics
GYRE
6.92
-0.12
-1.70%
Gyre Therapeutics
US · GYRE
#3470 by market cap
Listed 2006
6.92
-0.12
-1.70%
Live - 5344 symbols - heartbeat 342s ago
· 2026-10-08 09:51
Pre-market
7.04
0.00%
After-hours
7.04
0.00%
- Market cap
- 733.75M
- P/E (TTM)i
- -32.95
- P/Bi
- 6.80
- EPSi
- 0.02
- Div yieldi
- 0.00%
- 52W posi
- 37%
Reader sentiment
Are you bullish or bearish on GYRE?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Good
- Altman Z-Score is 19.42, above the 3.0 "safe zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 5 years
Latest year +10.24% YoY
Margins
- Gross margin
- 95.35%
- Operating margin
- 9.86%
- Net margin
- 4.31%
Key ratios & quality
- Altman Z-Scorei
- 19.42
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 89.59M | 102.29M | 113.45M | 105.76M | 116.59M |
| Gross profit | 85.57M | 97.50M | 108.81M | 101.87M | 111.17M |
| Selling & admin expenses | 48.33M | 71.61M | 75.82M | 73.62M | 85.98M |
| Research & development | 7.25M | 16.69M | 13.78M | 12.02M | 13.70M |
| Operating profit | 30.13M | 9.20M | 19.21M | 16.23M | 11.49M |
| Pretax profit | 29.60M | 9.41M | -76.97M | 23.22M | 14.44M |
| Tax | 6.17M | 5.10M | 8.52M | 5.32M | 4.56M |
| Net profit | 23.44M | 4.31M | -85.48M | 17.90M | 9.88M |
| Basic EPS | 0 | 0 | -1 | 0 | 0 |
| Diluted EPS | 0.31 | 0.03 | -1.41 | 0.05 | 0.02 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 22.06M | 29.73M | 30.56M | 37.20M | 22.52M | 29.11M |
| Gross profit | 21.16M | 28.58M | 28.94M | 35.45M | 21.29M | 26.90M |
| Selling & admin expenses | 15.80M | 22.47M | 19.65M | 30.52M | 21.36M | 21.62M |
| Research & development | 3.10M | 8.35M | 2.36M | 4.82M | 6.74M | 19.14M |
| Operating profit | 2.27M | -2.24M | 6.93M | 120.00K | -6.80M | -13.86M |
| Pretax profit | 4.64M | -1.58M | 7.63M | -66.00K | -9.24M | -14.43M |
| Tax | 901.00K | 662.00K | 1.69M | 1.30M | 621.00K | -164.00K |
| Net profit | 3.73M | -2.24M | 5.94M | -1.37M | -9.86M | -14.27M |
| Basic EPS | 0 | 0 | 0 | 0 | 0 | 0 |
| Diluted EPS | 0.00 | -0.03 | 0.03 | -0.02 | -0.10 | -0.12 |
Balance sheet
| Line item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total current assets | 44.85M | 49.65M | 57.22M | 64.79M | 102.37M |
| Cash & ST investments | 26.48M | 25.18M | 33.51M | 26.67M | 52.43M |
| Inventory | 5.72M | 6.12M | 4.28M | 6.34M | 10.17M |
| Total assets | 84.85M | 84.75M | 116.54M | 125.41M | 166.13M |
| Total current liabilities | 10.30M | 12.24M | 20.05M | 19.52M | 18.29M |
| Short-term debt | 486.81K | 492.00K | 210.00K | 713.00K | 636.00K |
| Long-term debt | -- | -- | -- | -- | -- |
| Total liabilities | 11,929,684.19 | 12,536,000.00 | 102,590,000.00 | 27,004,000.00 | 23,850,000.00 |
| Total equity | 72.92M | 72.22M | 13.95M | 98.40M | 142.28M |
| Retained earnings | 23.08M | 7.40M | -85.54M | -73.45M | -68.43M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 68.45M | 91.29M | 98.58M | 102.37M | 91.73M | 122.07M |
| Cash & ST investments | 29.89M | 54.37M | 60.05M | 52.43M | 49.81M | 74.80M |
| Inventory | 7.88M | 8.86M | 8.85M | 10.17M | 11.35M | 11.43M |
| Total assets | 129.79M | 152.65M | 159.38M | 166.13M | 162.02M | 199.26M |
| Total current liabilities | 18.99M | 16.92M | 15.91M | 18.29M | 19.79M | 28.66M |
| Short-term debt | 805.00K | 622.00K | 626.00K | 636.00K | 751.00K | 1.39M |
| Long-term debt | -- | -- | -- | -- | -- | -- |
| Total liabilities | 25,488,000.00 | 23,203,000.00 | 21,969,000.00 | 23,850,000.00 | 25,030,000.00 | 56,766,000.00 |
| Total equity | 104.30M | 129.44M | 137.42M | 142.28M | 136.99M | 142.49M |
| Retained earnings | -70.76M | -70.31M | -66.70M | -68.43M | -77.67M | -137.96M |
Cash flow
| Line item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating cash flow | 20.76M | 10.68M | 25.89M | -3.64M | 1.01M |
| Depreciation & amortization | 1.93M | 1.13M | 1.11M | 1.59M | 2.52M |
| Free cash flow | 12.30M | 5.68M | 17.31M | -6.77M | -913.00K |
| Dividends paid | 0 | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | -- | 0 | 773.00K | 23.51M |
| Ending cash balance | 26.09M | 25.18M | 33.51M | 11.81M | 37.07M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | -129.00K | -7.47M | 14.24M | -5.63M | 3.18M | -16.73M |
| Depreciation & amortization | 535.00K | 1.01M | 281.00K | 695.00K | 672.00K | 1.48M |
| Free cash flow | -950.00K | -7.83M | 13.63M | -5.77M | 3.00M | -18.01M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 509.00K | 23.00M | 0 | 0 | 0 | 0 |
| Ending cash balance | 15.05M | 56.37M | 40.40M | 37.07M | 37.50M | 43.29M |
Returns & efficiency
| Line item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| ROE %i | 32.14 | 26.79 | -248.87 | 50.89 | 5.94 |
| ROA %i | 27.62 | 23.33 | -84.72 | 9.99 | 3.45 |
| ROIC %i | 31.33 | 25.84 | -245.15 | 44.01 | 4.46 |
| 5-year avg ROE %i | -- | -- | -- | -- | -120.67 |
| EBIT margin %i | 33.18 | 27.73 | 16.94 | 15.35 | 9.86 |
| FCF / sales %i | 13.73 | 7.40 | 15.25 | -- | -- |
| Current ratioi | 4.36 | 4.06 | 2.85 | 3.32 | 5.60 |
| Quick ratioi | 3.80 | 3.46 | 2.51 | 2.86 | 4.89 |
| Debt / assetsi | 1.45 | 0.72 | 0.35 | 1.27 | 0.57 |
| LT debt / equityi | 1.02 | 0.28 | -- | 1.40 | 0.29 |
| Interest coveragei | 242.93 | 638.76 | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | 5.69 | 4.46 |
| Net income CAGR (3Y) %i | -- | -- | -- | -19.81 | 29.74 |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | 11.62 | 5.47 | 8.06 | 5.94 | -7.51 | -19.91 |
| ROA %i | 5.76 | 3.04 | 4.67 | 3.45 | -4.36 | -11.31 |
| ROIC %i | 11.45 | 5.35 | 7.92 | 4.46 | -7.40 | -20.28 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | 10.36 | 9.14 | 11.22 | 9.86 | 2.06 | -13.90 |
| FCF / sales %i | -- | -- | 1.26 | -- | 2.59 | -- |
| Current ratioi | 3.60 | 5.40 | 6.19 | 5.60 | 4.64 | 4.26 |
| Quick ratioi | 2.76 | 4.71 | 5.46 | 4.89 | 3.87 | 3.59 |
| Debt / assetsi | 1.22 | 0.91 | 0.73 | 0.57 | 0.51 | 1.72 |
| LT debt / equityi | 1.15 | 0.84 | 0.53 | 0.29 | 0.07 | 1.88 |
| Interest coveragei | -- | -- | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
✦ Quant Revenue Concentration how this is computed
Single-engine
- Gyre Pharmaceuticals is the largest reported line at 99.97% of revenue, across 2 reported segments.
- The next-largest line, Gyre, is a distant second at 0.03% - a sharp slowdown here would have little to offset it.
Revenue breakdown most recent period
Business
Gyre Pharmaceuticals99.97%
Quote time 2026-10-08 09:51:25 · For reference only, not investment advice and not tailored to your situation.